Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohong Han

Showing results (41-50 of 200) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?Xingshun Qi, Jia Jia, Daiming Fan, et al.
Journal of Hepatology|December 15, 2010
Stage of portal vein thrombosisXingshun Qi, Guohong Han, Ming Bai, et al.
The American Journal of Gastroenterology|February 9, 2010
A confusing relationship between Child-Turcotte-Pugh class A and compensated cirrhosisXingshun Qi, Guohong Han, Kaichun Wu, et al.
Journal of Hepatology|February 14, 2012
Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?Weijuan Wang, Yan Zhao, Guohong Han, et al.
Journal of Hepatology|March 25, 2014
ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: is it really applicable?Jian Wu, Wei Bai, Guohong Han, et al.
Journal of Hepatology|September 11, 2019
Reply to: "The "six-and-twelve score" for TACE treatment: Does it really help us?"Qiuhe Wang, Dongdong Xia, Wei Bai, et al.
Hepatology (Baltimore, Md.)|February 7, 2012
Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinomaYan Zhao, Man Yang, Xingshun Qi, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy - Authors' replyQiuhe Wang, Kai Li, Xulong Yuan, et al.
Annals of Gastroenterology|April 16, 2014
Portal hypertension complicating myelofibrosis in a patient without portal or hepatic vein thrombosisXingshun Qi, Jia Jia, Ming Bai, et al.
Journal of Gastroenterology and Hepatology|September 22, 2012
Education and Imaging. Hepatobiliary and pancreatic: inferior mesenteric vein-left gonadal vein shunt aggravating hepatic encephalopathyChuangye He, Xingshun Qi, Wengang Guo, et al.
Pageof 20

Showing results (41-50 of 200) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?Xingshun Qi, Jia Jia, Daiming Fan, et al.
Journal of Hepatology|December 15, 2010
Stage of portal vein thrombosisXingshun Qi, Guohong Han, Ming Bai, et al.
The American Journal of Gastroenterology|February 9, 2010
A confusing relationship between Child-Turcotte-Pugh class A and compensated cirrhosisXingshun Qi, Guohong Han, Kaichun Wu, et al.
Journal of Hepatology|February 14, 2012
Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?Weijuan Wang, Yan Zhao, Guohong Han, et al.
Journal of Hepatology|March 25, 2014
ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: is it really applicable?Jian Wu, Wei Bai, Guohong Han, et al.
Journal of Hepatology|September 11, 2019
Reply to: "The "six-and-twelve score" for TACE treatment: Does it really help us?"Qiuhe Wang, Dongdong Xia, Wei Bai, et al.
Hepatology (Baltimore, Md.)|February 7, 2012
Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinomaYan Zhao, Man Yang, Xingshun Qi, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy - Authors' replyQiuhe Wang, Kai Li, Xulong Yuan, et al.
Annals of Gastroenterology|April 16, 2014
Portal hypertension complicating myelofibrosis in a patient without portal or hepatic vein thrombosisXingshun Qi, Jia Jia, Ming Bai, et al.
Journal of Gastroenterology and Hepatology|September 22, 2012
Education and Imaging. Hepatobiliary and pancreatic: inferior mesenteric vein-left gonadal vein shunt aggravating hepatic encephalopathyChuangye He, Xingshun Qi, Wengang Guo, et al.
Pageof 20